Adolescents with partial human growth hormone HGH deficiency develop alterations of body composition after HGH discontinuation and require follow-up.
Tauber M - J Clin Endocrinol Metab - 01-NOV-2003; 88(11): 5101-6
From NIH/NLM MEDLINE
NLM Citation ID:
14602733 (PubMed)
Comment:
- J Clin Endocrinol Metab. 2003 Nov;88(11):5099-100
PubMed ID: 14602732
Full Source Title:
Journal of Clinical Endocrinology and Metabolism
Publication Type:
Journal Article
Language:
English
Author Affiliation:
Unit of Endocrinology, Hôpital des Enfants, TSA 70034, 31059 Toulouse Cedex 9, France. tauber.mt@chu-toulouse.fr
Authors:
Tauber M; Jouret B; Cartault A; Lounis N; Gayrard M; Marcouyeux C; Pienkowski C; Oliver I; Moulin P; Otal P; Joffre F; Arnaud C; Rochiccioli P
Abstract:
It is now a consensus to resume HGH treatment in adolescents with severe HGH deficiency (GHD) at retesting to prevent the occurrence of adult GHD syndrome. However, we do not have any data on the follow-up of adolescents with nonsevere GHD at completion of treatment. This report presents preliminary data from a 1-yr prospective study that includes the first 91 patients retested. Anthropometric data, IGF-I and IGF binding protein-3 levels, glycemia and insulinemia, lipid profile, and body composition using dual x-ray absorptiometry and abdominal computed tomography scan were recorded at completion of HGH treatment and 1 yr later. Body composition was significantly different at both evaluations, with increased total body fat and decreased lean body mass in the partial GHD group vs. the normal group. Moreover, these alterations worsened after 1 yr without GH in the partial GHD group, whereas there were no modifications in the normal group. We did not find any metabolic alterations such as elevated triglyceride, total cholesterol, or insulin levels. Adolescents with reconfirmed partial GHD exhibit alterations in body composition after 1 yr without HGH, whereas those retested normal do not. These changes are similar to those described in severe GHD, although less marked, and justify a precise follow-up.
Major Subjects:
- Body Composition / * drug effects
- Growth Disorders / * drug therapy / radiography
- Growth Hormone / * administration & dosage / adverse effects / * deficiency
Additional Subjects:
- Abdomen
- Adipose Tissue / radiography
- Adolescent
- Blood Glucose
- Bone Density
- Child
- Female
- Follow-Up Studies
- Humans
- Insulin-Like Growth Factor Binding Protein 3 / blood
- Insulin-Like Growth Factor I / metabolism
- Lipids / blood
- Male
- Prospective Studies
- Substance Withdrawal Syndrome / diagnosis
Chemical Compound Name:
(Blood Glucose); (Insulin-Like Growth Factor Binding Protein 3); (Lipids); 67763-96-6(Insulin-Like Growth Factor I); 9002-72-6(Growth Hormone)